Dyslipidemia in HIV-infected individuals: From pharmacogenetics to pharmacogenomics

Pharmacogenomics

Volumn 11, Issue 4, 2010, Pages 587-594

  Tarr, Philip E ^a   Rotger, Margalida ^b   Telenti, Amalio ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Antiretroviral therapy; Dyslipidemia; Genome wide association study; HIV; Metabolic complications; Pharmacogenetics; SNP

Indexed keywords

ABC TRANSPORTER A1; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E5; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROGENESIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; HEREDITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERTRIGLYCERIDEMIA; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTI-HIV AGENTS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIAS; GENOME, HUMAN; HIV INFECTIONS; HUMANS; LIPIDS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77950344979     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.35     Document Type: Review

References (80)

1. Currier JS, Kendall MA, Henry WK et al.: Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults. AIDS 21, 1137-1145 (2007).
2. Friis-Moller N, Reiss P, Sabin CA et al.: Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
3. Triant VA, Lee H, Hadigan C, Grinspoon SK: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodefciency virus disease. J. Clin. Endocrinol. Metab. 92, 2506-2512 (2007)
4. D'Arminio A, Sabin CA, Phillips AN et al.: Cardio-and cerebrovascular events in HIV-infected persons. AIDS 18, 1811-1817 (2004).
5. Periard D, Cavassini M, Taffe P et al.: High prevalence of peripheral arterial disease in HIV-infected persons. Clin. Infect. Dis. 46, 761-767 (2008).
6. Obel N, Thomsen HF, Kronborg G et al.: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin. Infect. Dis. 44, 1625-1631 (2007).
7. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296 (2006).
8. + T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 22, 1615-1624 (2008).
9. Calmy A, Gayet-Ageron A, Montecucco F et al.: HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 23, 929-939 (2009).
10. Stein JH, Klein MA, Bellehumeur JL et al.: Use of human immunodefciency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104, 257-262 (2001).
11. van Vonderen MG, Hassink EA, van Agtmael MA et al.: Increase in carotid artery intima-media thickness and arterial stiffness but improvement in several markers of endothelial function after initiation of antiretroviral therapy. J. Infect. Dis. 199, 1186-1194 (2009).
12. Madden E, Lee G, Kotler DP et al.: Association of antiretroviral therapy with fbrinogen levels in HIV-infection. AIDS 22, 707-715 (2008).
13. Ledergerber B, Furrer H, Rickenbach M et al.: Factors associated with the incidence of Type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin. Infect. Dis. 45, 111-119 (2007).
14. De Wit S, Sabin CA, Weber R et al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 31, 1224-1229 (2008).
15. Riddler SA, Li X, Otvos J et al.: Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J. Acquir. Immune Defc. Syndr. 48, 281-288 (2008).
16. Periard D, Telenti A, Sudre P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100, 700-705 (1999).
17. Fontas E, van Leth F, Sabin CA et al.: Lipid profles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profles? J. Infect. Dis. 189, 1056-1074 (2004).
18. Young J, Weber R, Rickenbach M et al.: Lipid profles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir. Ther. 10, 585-591 (2005). (Pubitemid 41224950)
19. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN: Hypertriglyceridemia in the acquired immunodefciency syndrome. Am. J. Med. 86, 27-31 (1989).
20. Riddler SA, Smit E, Cole SR et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 289, 2978-2982 (2003).
21. Tarr PE, Telenti A: Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir. Ther. 12, 999-1013 (2007).
22. International HapMap Consortium: A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
23. Frazer KA, Murray SS, Schork NJ, Topol EJ: Human genetic variation and its contribution to complex traits. Nat. Rev. Genet. 10, 241-251 (2009).
24. Visscher PM, Montgomery GW: Genome-wide association studies and human disease: from trickle to food. JAMA 302, 2028-2029 (2009).
25. Pilia G, Chen WM, Scuteri A et al.: Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 2, E132 (2006).
26. Souren NY, Paulussen AD, Loos RJ et al.: Anthropometry, carbohydrate and lipid metabolism in the East Flanders prospective twin survey: heritabilities. Diabetologia 50, 2107-2116 (2007).
27. Lister RK, Youle M, Nair DR, Winder AF, Rustin MH: Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 353, 1678 (1999).
28. Behrens G, Schmidt HH, Stoll M, Schmidt RE: ApoE genotype and proteaseinhibitor-associated hyperlipidaemia. Lancet 354, 76 (1999).
29. Tarr PE, Taffe P, Bleiber G et al.: Modeling the infuence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191, 1419-1426 (2005).
30. Talmud PJ, Hawe E, Martin S et al.: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11, 3039-3046 (2002).
31. Song Y, Stampfer MJ, Liu S: Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141, 137-147 (2004).
32. Bennet AM, Di Angelantonio E, Ye Z et al.: Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 298, 1300-1311 (2007).
33. Fauvel J, Bonnet E, Ruidavets JB et al.: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15, 2397-2406 (2001).
34. Spirin V, Schmidt S, Pertsemlidis A, Cooper RS, Cohen JC, Sunyaev SR: Common single-nucleotide polymorphisms act in concert to affect plasma levels of high-density lipoprotein cholesterol. Am. J. Hum. Genet. 81(6) (2007) (Epub ahead of print).
35. Kathiresan S, Melander O, Anevski D et al.: Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358, 1240-1249 (2008).
36. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
37. Arnedo M, Taffe P, Sahli R et al.: Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genomics 17, 755-764 (2007).
38. Foulkes AS, Wohl DA, Frank I et al.: Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 3, E52 (2006).
39. Chang SY, Ko WS, Kao JT et al.: Association of single-nucleotide polymorphism 3 and c.553GT of APOA5 with hypertriglyceridemia after treatment with highly active antiretroviral therapy containing protease inhibitors in HIV-infected individuals in Taiwan. Clin. Infect. Dis. 48, 832-835 (2009).
40. Freimer NB, Sabatti C: Guidelines for association studies in human molecular genetics. Hum. Mol. Genet. 14, 2481-2483 (2005).
41. Colhoun HM, McKeigue PM, Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
42. Saxena R, Voight BF, Lyssenko V et al.: Genome-wide association analysis identifes loci for Type 2 diabetes and triglyceride levels. Science 316, 1331-1336 (2007).
43. Sandhu MS, Waterworth DM, Debenham SL et al.: LDL-cholesterol concentrations: a genome-wide association study. Lancet 371, 483-491 (2008).
44. Kathiresan S, Melander O, Guiducci C et al.: Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189-197 (2008).
45. Willer CJ, Sanna S, Jackson AU et al.: Newly identifed loci that infuence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40(2), 161-169 (2008).
46. Wallace C, Newhouse SJ, Braund P et al.: Genome-wide association study identifes genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82, 139-149 (2008).
47. Chasman DI, Pare G, Zee RY et al.: Genetic loci associated with plasma concentration of LDL-C, HDL-C, triglycerides, ApoA1, and ApoB among 6382 Caucasian women in genome-wide analysis with replication. Circ. Cardiovasc. Genet. 1, 21-30 (2008).
48. Aulchenko YS, Ripatti S, Lindqvist I et al.: Loci infuencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat. Genet. 41, 47-55 (2009).
49. Kathiresan S, Willer CJ, Peloso GM et al.: Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41, 56-65 (2009).
50. Sabatti C, Service SK, Hartikainen AL et al.: Genome-wide association analysis of metabolic traits in a birth cohort from a founder population. Nat. Genet. 41, 35-46 (2009).
51. Rotger M, Bayard C, Taffé P: Contribution of genome-wide signifcant single nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals a longitudinal study. Circ. Cardiovasc. Genet. 2(6), 621-628 (2009).
52. Hoeg JM, Feuerstein IM, Tucker EE: Detection and quantitation of calcifc atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler. Thromb. 14, 1066-1074 (1994).
53. Brown MS, Goldstein JL: Biomedicine. Lowering LDL-not only how low, but how long? Science 311, 1721-1723 (2006).
54. Malavazi I, Abrao EP, Mikawa AY, Landgraf VO, da Costa PI: Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profles: the relevance of apolipoprotein E genotypes and immunological status. Clin. Chem. Lab. Med. 42, 525-532 (2004).
55. Meigs JB, Shrader P, Sullivan LM et al.: Genotype score in addition to common risk factors for prediction of Type 2 diabetes. N. Engl. J. Med. 359, 2208-2219 (2008).
56. Lyssenko V, Jonsson A, Almgren P et al.: Clinical risk factors, DNA variants, and the development of Type 2 diabetes. N. Engl. J. Med. 359, 2220-2232 (2008).
57. Manolio TA: Cohort studies and the genetics of complex disease. Nat. Genet. 41, 5-6 (2009).
58. Manolio TA, Collins FS, Cox NJ: Finding the missing heritability of complex diseases. Nature 461(7265), 747-753 (2009).
59. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH: Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 305, 869-872 (2004).
60. Romeo S, Pennacchio LA, Fu Y et al.: Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat. Genet. 39, 513-516 (2007).
61. Bodmer W, Bonilla C: Common and rare variants in multifactorial susceptibility to common diseases. Nat. Genet. 40, 695-701 (2008).
62. Scott LJ, Mohlke KL, Bonnycastle LL et al.: A genome-wide association study of Type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341-1345 (2007).
63. Zeggini E, Scott LJ, Saxena R et al.: Meta-analysis of genome-wide association data and large-scale replication identifes additional susceptibility loci for Type 2 diabetes. Nat. Genet. 40, 638-645 (2008).
64. Thorleifsson G, Walters GB, Gudbjartsson DF et al.: Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. Nat. Genet. 41, 18-24 (2009).
65. Meyre D, Delplanque J, Chevre JC et al.: Genome-wide association study for early-onset and morbid adult obesity identifes three new risk loci in European populations. Nat. Genet. 41, 157-159 (2009).
66. Newton-Cheh C, Johnson T, Gateva V et al.: Genome-wide association study identifes eight loci associated with blood pressure. Nat. Genet. (2009) (Epub ahead of print).
67. Levy D, Ehret GB, Rice K et al.: Genome-wide association study of blood pressure and hypertension. Nat. Genet. (2009) (Epub ahead of print).
68. Helgadottir A, Thorleifsson G, Manolescu A et al.: A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 316, 1491-1493 (2007). (Pubitemid 46906618)
69. Samani NJ, Erdmann J, Hall AS et al.: Genomewide association analysis of coronary artery disease. N. Engl. J. Med. 357, 443-453 (2007). (Pubitemid 47204873) (Pubitemid 47204873)
70. McPherson R, Pertsemlidis A, Kavaslar N et al.: A common allele on chromosome 9 associated with coronary heart disease. Science 316, 1488-1491 (2007).
71. Rotger M, Gsponer T, Martinez R, Ledergerber B, Telenti A, Tarr PE: Contribution of genome-wide signifcant single nucleotide polymorphisms to new-onset diabetes mellitus in HIV-infected subjects receiving antiretroviral therapy. Presented at: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 16-19 February 2010 (Abstract O-233).
72. Nolan D, Moore C, Castley A et al.: Tumour necrosis factor-a gene-238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17, 121-123 (2003).
73. Martin AM, Hammond E, Nolan D et al.: Accumulation of mitochondrial DNA mutations in human immunodefciency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am. J. Hum. Genet. 72, 549-560 (2003).
74. Hulgan T, Tebas P, Canter JA et al.: Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. J. Infect. Dis. 197, 858-866 (2008).
75. Nasi M, Guaraldi G, Orlando G et al.: Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy. Clin. Infect. Dis. 47, 962-968 (2008).
76. Zanone Poma B, Riva A, Nasi M et al.: Genetic polymorphisms differently infuencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22, 1769-1778 (2008).
77. Hendrickson SL, Kingsley LA, Ruiz-Pesini E et al.: Mitochondrial DNA haplogroups infuence lipoatrophy after highly active antiretroviral therapy. J. Acquir. Immune Defc. Syndr. 51, 111-116 (2009).
78. Ranade K, Geese WJ, Noor M et al.: Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 22, 1561-1568 (2008).
79. Wangsomboonsiri WM, Chantarangsu S: Association between HLA-B*4001 and Lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin. Infect. Dis. 50(4), 597-604 (2010).
80. Shresta S: A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS 24(4), 583-592 (2010).